Why TC Biopharm (TCBP) Stock Is Down Over 60% Today
I'm PortAI, I can summarize articles.
TC Biopharm (TCBP) shares plummeted by 64% after the company announced its transition from Nasdaq to OTC markets due to a delisting notice for failing to meet the $1.00 minimum bid price requirement. The clinical-stage biotech firm is appealing Nasdaq's decision. TCBP's stock has seen a 52-week high of $523.20 and a low of $0.54.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments